FCS

Fort Lauderdale to Host the Inaugural Florida Beach Bowl, Showcasing Achievements in Collegiate Football

Retrieved on: 
Thursday, June 8, 2023
Football, Historically black colleges and universities, Culture, HBCU, Senior advisor, Golf, Duluth All-City Golf Tournament, Athlete, School, City, Restaurant, Love, Economic development, Sport, FCS, Amusement park, Hotel

FORT LAUDERDALE, Fla., June 8, 2023 /PRNewswire-PRWeb/ -- The highly anticipated Florida Beach Bowl is set to take place on December 28, 2023, at the DRV Pink Stadium in Fort Lauderdale. This inaugural event promises to deliver an unforgettable experience for both players and fans, featuring a Historically Black College or University (HBCU) team and a Football Championship Subdivision (FCS) football team battling it out on the sun-drenched shores of South Florida.

Key Points: 
  • The highly anticipated Florida Beach Bowl is set to take place on December 28, 2023, at the DRV Pink Stadium in Fort Lauderdale.
  • FORT LAUDERDALE, Fla., June 8, 2023 /PRNewswire-PRWeb/ -- The highly anticipated Florida Beach Bowl is set to take place on December 28, 2023, at the DRV Pink Stadium in Fort Lauderdale.
  • By uniting an HBCU and an FCS football team program, the Florida Beach Bowl celebrates the rich diversity and talent within collegiate athletics.
  • Daphnee Sainvil, Economic Development Manager for the City of Fort Lauderdale, shared her enthusiasm, "We are thrilled to host the Florida Beach Bowl in our beautiful city.

Florida Cancer Specialists & Research Institute President & Managing Physician Lucio N. Gordan, MD Evaluates the Impact of Genomic Profiling

Retrieved on: 
Thursday, June 1, 2023
Database, Genomics, Biomarker, Science, NCS, Patient, Investment, Physician, Medicine, Gene, FCS, Nursing, Medical imaging, Illumina, MD

FORT MYERS, Fla., June 1, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) President & Managing Physician Lucio N. Gordan, MD , will join an expert panel of precision medicine leaders in Chicago this weekend to discuss the impact of genomic profiling.

Key Points: 
  • FORT MYERS, Fla., June 1, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) President & Managing Physician Lucio N. Gordan, MD , will join an expert panel of precision medicine leaders in Chicago this weekend to discuss the impact of genomic profiling.
  • "Genomic profiling has made a profound impact on our practice, our industry, and most importantly, our patients," says Dr. Gordan.
  • Following the opening, the statewide practice developed an internal precision oncology team and database to better serve patients through genomic profiling.
  • "The investments we are making today are propelling us into a future where precision oncology is the standard of care.

Florida Cancer Specialists & Research Institute Cutting-Edge Clinical Research Presented at 2023 ASCO® Annual Meeting

Retrieved on: 
Thursday, June 1, 2023
Abstract (summary), Education, Pulmonary embolism, Head, FACP, Cancer, Uveal melanoma, Research, Publication, Lung cancer, Doctor of Philosophy, ASCO, Clonal hematopoiesis, American Society of Clinical Oncology, MD, Patient, Physician, Melanoma, Annual general meeting, Drug development, Ovarian cancer, Breast cancer, Health, Society, Conference, FCS, Nursing, Pharmaceutical industry, Dietary supplement, Birth control, Medical imaging, Glass wool

FORT MYERS, Fla., June 1, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) physicians are presenting the outcomes of 23 clinical trials, the majority being Phase 1, at the 2023 American Society of Clinical Oncology (ASCO®) Annual Meeting on June 2 – 6 in Chicago, Illinois. With over 120 abstract sub-categories, attendees will learn about the most advanced treatments, research and innovations in oncology care on a global scale.

Key Points: 
  • Florida Cancer Specialists & Research Institute to present 23 abstracts/publications at 2023 ASCO Annual Conference.
  • Many of the featured studies being presented at the 2023 ASCO® Annual Meeting originated from trials conducted at the three FCS Phase 1 Drug Development Units and from late-phase studies conducted at FCS clinics located throughout Florida.
  • The American Society of Clinical Oncology (ASCO®) represents nearly 45,000 oncology professionals who care for people living with all forms of cancer.
  • Through research, education and promotion of high quality and equitable patient care, ASCO works to conquer cancer.

Advanced Molecular Genetic Testing and Clinical Trial Research Capabilities Improve Care Quality and Reduce Costs for Medicare Cancer Patients

Retrieved on: 
Wednesday, May 31, 2023
CVS, Hope, Medicare, MD, Patient, Physician, Investment, Cancer, Drug development, Gene, FCS, Nursing

FORT MYERS, Fla., May 31, 2023 /PRNewswire/ -- A collaborative effort of Florida Cancer Specialists & Research Institute, LLC (FCS) and CVS Health/Aetna to integrate cancer care advancements within a value-driven framework is delivering improved quality and cost savings for Medicare patients enrolled in the insurer's Oncology Medical Home Program. The initiative integrates cancer care advancements pioneered by the statewide practice into the cycle of care for patients diagnosed with 18 specific cancers. Details are documented in a newly-released case study.

Key Points: 
  • Results of year-long collaborative effort between Florida Cancer Specialists & Research Institute and CVS Health/Aetna documented in newly released case study.
  • The initiative integrates cancer care advancements pioneered by the statewide practice into the cycle of care for patients diagnosed with 18 specific cancers.
  • These specific efforts resulted in more positive outcomes for our patients with an overall better patient experience, at a lower cost."
  • Additionally, FCS achieved shared savings, demonstrating the statewide practice's consistent ability to provide high-quality care to patients at a lower cost.

Federal Reserve consumer payment survey shows continuation of pandemic trends, including rising credit card usage and enduring demand to hold cash

Retrieved on: 
Friday, May 19, 2023
Banking, Personal Finance, Technology, Professional Services, Other Consumer, Payments, Other Professional Services, Networks, Fintech, Consumer, Finance, Federal Reserve Bank, Public, COVID-19, Research, Key, Diary, Federal Reserve Bank of San Francisco, Federal Reserve, FCS, Bank, Cryptocurrency

The Federal Reserve System’s FedCash® Services (FCS) released a report from its ongoing research into the payment habits of the U.S. population.

Key Points: 
  • The Federal Reserve System’s FedCash® Services (FCS) released a report from its ongoing research into the payment habits of the U.S. population.
  • The 2023 findings from Diary of Consumer Payment Choice finds that consumer payment behavior remains consistent with the early pandemic, including a shift toward credit card payments and a slight decrease in the share of cash-based transactions.
  • The average amount of cash held in adults’ pocket, purse, or wallet rose to $73, reflecting a recent trend of higher consumer interest in holding cash.
  • “Consumers have continued to use credit cards – the most used payment method in 2022 – more often.

Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome

Retrieved on: 
Tuesday, May 16, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Arrowhead, Trust, PALISADE, Arrowhead Pharmaceuticals, Patient, Dura Pharmaceuticals, Inc. v. Broudo, FCS, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has completed enrollment of its global Phase 3 clinical trial (PALISADE) evaluating ARO-APOC3 for the treatment of familial chylomicronemia syndrome.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has completed enrollment of its global Phase 3 clinical trial (PALISADE) evaluating ARO-APOC3 for the treatment of familial chylomicronemia syndrome.
  • The company anticipates that the primary portion of the study will be complete in the second quarter of 2024 with a data readout shortly thereafter and subsequent submissions for regulatory review and approval.
  • Javier San Martin, M.D., chief medical officer at Arrowhead, said: “Completing enrollment of the Phase 3 PALISADE study represents a significant milestone for Arrowhead and brings our potentially important RNAi-based medicines closer to the patients that may benefit from them.
  • I am grateful to the FCS patient community and principal investigators for their trust and participation in the PALISADE study.”

Nationwide Drug Shortage Calls for Immediate Reform on Pricing Regulation for Generic Drugs

Retrieved on: 
Monday, May 15, 2023
University of Florida Cancer and Genetics Research Complex, ASP, Breast, Carboplatin, Lung, Government, Pharmacist, Patient, Physician, Oncology, Cisplatin, Health, FCS, Property management, Nursing, Medical device, Pharmaceutical industry, MD

FORT MYERS, Fla., May 15, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is demanding reform in the pricing regulation of generic drugs, an issue that has deeply affected the oncology community for years but has worsened in recent months. Inadequacies in regulating average selling prices (ASP) for regimens crucial to patient care are directly affecting manufacturers' ability to maintain operations and productivity for critical generic drugs.

Key Points: 
  • Inadequacies in regulating average selling prices (ASP) for regimens crucial to patient care are directly affecting manufacturers' ability to maintain operations and productivity for critical generic drugs.
  • Oncology leaders from Florida Cancer Specialists & Research Institute call for pricing reform of generic cancer drugs.
  • The ask is for all involved or concerned to bring this issue to light with their state legislators and demand pricing regulation that will ensure ample supplies.
  • We must take action now to instill regulatory pricing that will enable consistent and reliable production of these critical drugs."

Armored Vehicle Market to be Worth $44.56 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Thursday, May 11, 2023
Weapon, Complex sales, Human, Travel, Armed Forces of Saudi Arabia, Combat, Rheinmetall, Ministry of Defence Industry of Azerbaijan, Armed, Uranium, Block cipher mode of operation, USD, Stainless steel, Sale, Revenue, Ministry, Fire-control system, Austro-Hungarian Armed Forces, Risk, SAN, Artificial intelligence, Mobility, Growth, Convention (norm), OEM, Longevity, Slovakia, Combat support, Conference, FCS, Renewable energy, Arms industry, Rail transport, Retail, Gidran

SAN FRANCISCO, May 11, 2023 /PRNewswire/ -- The global armored vehicle market size is anticipated to reach USD 44.56 billion by 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, May 11, 2023 /PRNewswire/ -- The global armored vehicle market size is anticipated to reach USD 44.56 billion by 2030, according to a new report by Grand View Research, Inc.
  • The growing internal and external terrorist activities across the globe are expected to drive the market demand over the forecast period.
  • The wheeled segment led the market in 2022 accounting for over 70% of the global revenue share.
  • Grand View Research has segmented the global armored vehicle market based on product, type, mobility, mode of operation, point of sale, system, and region:
    Armored Vehicle Market - Product Outlook (Revenue, USD Million, 2017 - 2030)

Armored Vehicle Market to be Worth $44.56 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Thursday, May 11, 2023
Weapon, Complex sales, Human, Travel, Armed Forces of Saudi Arabia, Combat, Rheinmetall, Ministry of Defence Industry of Azerbaijan, Armed, Uranium, Block cipher mode of operation, USD, Stainless steel, Sale, Revenue, Ministry, Fire-control system, Austro-Hungarian Armed Forces, Risk, SAN, Artificial intelligence, Mobility, Growth, Convention (norm), OEM, Longevity, Slovakia, Combat support, Conference, FCS, Renewable energy, Arms industry, Rail transport, Retail, Gidran

SAN FRANCISCO, May 11, 2023 /PRNewswire/ -- The global armored vehicle market size is anticipated to reach USD 44.56 billion by 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, May 11, 2023 /PRNewswire/ -- The global armored vehicle market size is anticipated to reach USD 44.56 billion by 2030, according to a new report by Grand View Research, Inc.
  • The growing internal and external terrorist activities across the globe are expected to drive the market demand over the forecast period.
  • The wheeled segment led the market in 2022 accounting for over 70% of the global revenue share.
  • Grand View Research has segmented the global armored vehicle market based on product, type, mobility, mode of operation, point of sale, system, and region:
    Armored Vehicle Market - Product Outlook (Revenue, USD Million, 2017 - 2030)

Florida Cancer Specialists & Research Institute Delivers Value to Patients Through Strategic Partnerships

Retrieved on: 
Tuesday, May 9, 2023
OCM, APO, Oncology Care Model, CMMI, Medicare, Center for Medicare and Medicaid Innovation, Patient, Paul Walcker, MIPS, FCS, Nursing, MD

FORT MYERS, Fla., May 9, 2023 /PRNewswire/ -- A known leader in value-based oncology care, Florida Cancer Specialists & Research Institute, LLC (FCS) continues to forge new partnerships with alternative payment models and payers.

Key Points: 
  • FORT MYERS, Fla., May 9, 2023 /PRNewswire/ -- A known leader in value-based oncology care, Florida Cancer Specialists & Research Institute, LLC (FCS) continues to forge new partnerships with alternative payment models and payers.
  • "This was the launching point for the several value-based care partnerships and programs we are currently pursuing today."
  • Stemming from lessons learned during its participation in OCM, FCS has expanded its efforts to create value for patients by working closely with the payer community.
  • "FCS will continue its quest to drive value-based care initiatives through strategic and innovative models and partnerships," continues Walcker.